Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Can A REMS Mitigate CV Risks? Avandia, Meridia Offer Point, Counterpoint

Jan 15 2019

• By Sue Sutter

3D illustration of a matrix with tablets and the words risks and benefits. Concept of clinical trials results - Illustration

Related Content

FDA Replaces Avandia REMS Distribution Restrictions With Prescriber Training

Nov 26 2013

Takeda’s Uloric: CV Mortality Signal Leads US FDA To Ponder Regulatory Options

Jan 10 2019

Is There A REMS In Uloric’s Future? US FDA Panelists Say Yes, Agency Says Not Likely

Jan 12 2019

Score One For FDAAA: Uloric Approval Was Clinched By Post-Market Powers

Jul 01 2010

FDA Polled Review Staff On <em>Avandia</em> REMS Changes

Dec 02 2013

REMS Cannot Save Abbott's Obesity Drug Meridia In Face Of Cardiovascular Issues

Oct 08 2010

FDA, EMA Decisions On Avandia Reflect The Power Of REMS

Sep 27 2010

Related Companies

Takeda Pharmaceutical Co. Ltd.

GSK plc

Abbott

Additional Topics

United States Advisory Committees Drug Safety Post Market Regulation & Studies Regulation BioPharmaceutical Inflammation

More from US FDA Performance Tracker

More from Regulatory Trackers

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window